These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63. Amylin-induced downregulation of hippocampal neurogenesis is attenuated by leptin in a STAT3/AMPK/ERK-dependent manner in mice. Moon HS; Dincer F; Mantzoros CS Diabetologia; 2013 Mar; 56(3):627-34. PubMed ID: 23224631 [TBL] [Abstract][Full Text] [Related]
64. A platform for studying the transfer of Chlamydia pneumoniae infection between respiratory epithelium and phagocytes. Kortesoja M; Trofin RE; Hanski L J Microbiol Methods; 2020 Apr; 171():105857. PubMed ID: 32006529 [TBL] [Abstract][Full Text] [Related]
70. Facial soft tissue volume decreases during metreleptin treatment in patients with partial and generalized lipodystrophy. Miehle K; Stumvoll M; Fasshauer M; Hierl T Endocrine; 2017 Nov; 58(2):262-266. PubMed ID: 28993984 [TBL] [Abstract][Full Text] [Related]
71. Peculiarities of Intracellular Signal Transduction in the Regulation of Functions of Mesenchymal, Neural, and Hematopoietic Progenitor Cells. Zyuz'kov GN; Zhdanov VV; Udut EV; Miroshnichenko LA; Polyakova TY; Stavrova LA; Chaikovskii AV; Simanina EV; Minakova MY; Udut VV Bull Exp Biol Med; 2019 Jun; 167(2):201-206. PubMed ID: 31236885 [TBL] [Abstract][Full Text] [Related]
72. Clinical Trials Required to Assess Potential Benefits and Side Effects of Treatment of Patients With Anorexia Nervosa With Recombinant Human Leptin. Hebebrand J; Milos G; Wabitsch M; Teufel M; Führer D; Bühlmeier J; Libuda L; Ludwig C; Antel J Front Psychol; 2019; 10():769. PubMed ID: 31156489 [TBL] [Abstract][Full Text] [Related]
73. Effects of polydimethylsiloxane membrane surface treatments on human uterine smooth muscle cell strain response. Marr EE; Isenberg BC; Wong JY Bioact Mater; 2024 Feb; 32():415-426. PubMed ID: 37954466 [TBL] [Abstract][Full Text] [Related]
75. The Metreleptin Effectiveness and Safety Registry (MEASuRE): concept, design and challenges. Haymond MW; Araújo-Vilar D; Balser J; Lewis JH; Louzado R; Musso C; von Schnurbein J; Wabitsch M; Orphanet J Rare Dis; 2023 May; 18(1):127. PubMed ID: 37237416 [TBL] [Abstract][Full Text] [Related]
76. Metreleptin treatment for congenital generalized lipodystrophy type 4 (CGL4): a case report. Takeyari S; Takakuwa S; Miyata K; Yamamoto K; Nakayama H; Ohata Y; Fujiwara M; Kitaoka T; Kubota T; Namba N; Sakai N; Ozono K Clin Pediatr Endocrinol; 2019; 28(1):1-7. PubMed ID: 30745727 [TBL] [Abstract][Full Text] [Related]
77. Adherence with metreleptin therapy and health self-perception in patients with lipodystrophic syndromes. Vatier C; Kalbasi D; Vantyghem MC; Lascols O; Jéru I; Daguenel A; Gautier JF; Buyse M; Vigouroux C Orphanet J Rare Dis; 2019 Jul; 14(1):177. PubMed ID: 31300002 [TBL] [Abstract][Full Text] [Related]
78. First Account of Psychological Changes Perceived by a Female with Congenital Leptin Deficiency upon Treatment with Metreleptin. Hebebrand J; Zorn S; Antel J; von Schnurbein J; Wabitsch M; Gradl-Dietsch G Obes Facts; 2022; 15(5):730-735. PubMed ID: 35952649 [TBL] [Abstract][Full Text] [Related]
79. [Hyperpigmented macula: An adverse reaction of treatment with metreleptin]. Araújo-Vilar D; Quinteiro S; Fernández-Pompo A; Sánchez-Iglesias S An Pediatr (Engl Ed); 2020 Oct; 93(4):270-271. PubMed ID: 31753723 [No Abstract] [Full Text] [Related]
80. Early intracellular signaling events induced by in vitro metreleptin administration in cardiac myocytes and uterine smooth muscle cells. Choi SK; Park S; Choi Y; Moon HS Cell Mol Biol (Noisy-le-grand); 2015 Aug; 61(4):15-20. PubMed ID: 26255263 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]